GSK to Acquire Efimosfermin, a Phase III-Ready Potential Best-in-Class Specialty Medicine to Treat, and Prevent Progression of Steatotic Liver Disease (SLD)

GSK plc and Boston Pharmaceuticals announced that they have entered into an agreement under which GSK will acquire Boston Pharmaceuticals’ lead asset, efimosfermin alfa.